Interleukin 2 (IL-2) mediates the regression of metastatic cancer but clinical use has been limited due to associated toxicities. Tumor necrosis factor (TNF) is an important mediator of IL-2 toxicity and may have a limited role in IL-2 antitumor efficacy. Because pentoxifylline (PTXF) inhibits TNF production, we hypothesized that PTXF would ameliorate IL-2 toxicity without compromising antitumor efficacy. Four groups of female C57BL/6 mice with pulmonary metastases from a 3-methylcholanthrene-induced fibrosarcoma (MCA-105) and four groups of nontumored mice were treated every 6 h for 4 d by intraperitoneal injections of either IL-2 alone, IL-2 and PTXF, PTXF alone, or equal volumes of saline. Upon completion of therapy, we found that PTXF suppressed many of the IL-2-induced effects including TNF production, lymphocytic infiltration of multiple organs, multiple organ edema, hepatic dysfunction, leukopenia, and thrombocytopenia. Tumor response was determined 21 d after cessation of therapy by quantitating the number and surface area of pulmonary metastases. PTXF preserved antitumor efficacy while reducing the morbidity and mortality caused by IL-2 treatment. These data strongly support the use of PTXF in extending the therapeutic index of IL-2 in the treatment of cancer. (J. Clin. Invest. 1992. 90:637-641.)
Introduction
Interleukin 2 (IL-2) mediates the regression of certain human malignancies. Clinical trials demonstrate that response rates with IL-2 therapy for melanoma and renal cell carcinoma are comparable, or superior, to the best regimens of conventional chemotherapeutic agents (1) . IL-2 therapy has, however, been associated with the development of dose-dependent systemic toxicities of sufficient severity to limit therapeutic efficacy and preclude clinical application for most patients (2) . The IL-2-induced toxicities ofprimary clinical significance occur second-ary to a "vascular leak syndrome" and include diffuse tissue edema, weight gain, decreased systemic vascular resistance with hypotension, acute respiratory distress, and hepatic and renal dysfunction.
The mechanism for the IL-2-induced vascular leak syndrome and related toxicities are not completely understood. However, they are remarkably similar to the systemic responses seen in severe infection or injury where tumor necrosis factor (TNF)' is an important mediator (3) . Previous studies also show that IL-2 induces macrophage production of TNF (4) , and increased levels ofplasma TNF have been measured in patients treated with IL-2 (5). In addition, Fraker et al. (6) demonstrated that passive immunization against TNF partially abrogated IL-2 toxicity in C57BL/6 mice, while the antitumor effect of IL-2 against pulmonary metastasis was maintained. Collectively, these studies suggest that the secondarily induced cytokine TNF is most likely a primary mediator of IL-2 toxicity, and that treatment strategies aimed to inhibit the production ofTNF hold promise for extending the therapeutic index of IL-2. We hypothesized that one such treatment could involve the use of pentoxifylline (PTXF).
PTXF suppresses macrophage TNF gene transcription and increases the survival rate in murine endotoxic shock (7, 8) . In addition, PTXF prevents IL-2-induced lung injury in guinea pigs (9) and also inhibits IL-2-induced leukocyte-endothelial adherence while reducing systemic toxicity (10) . The present study tested the effects of PTXF on IL-2-induced systemic toxicities and on IL-2 antitumor efficacy.
The data of our investigation clearly show that PTXF suppresses the IL-2 induction of increased circulating levels of TNF as well as the IL-2 induction oflymphocyte infiltration in various organs while ameliorating IL-2 treatment toxicity. Most importantly, this inhibition oftoxicity occurred while the antitumor efficacy of IL-2 was maintained. Experimental design. Female C57BL/6 mice were allowed to acclimate to their surroundings for 1 wk before the initiation ofthe experiments. In the first series of experiments, nontumored C57BL/6 mice were randomly divided into four groups (Table I ) and were injected with 0.1-ml intraperitoneal injections as follows: The first group (IL-2 alone) received 100,000 U of IL-2 every 6 h and saline every 12 h. The second group (IL-2 and PTXF) was given 100,000 U of IL-2 every 6 h and 50 mg/kg PTXF every 12 h. The third group (PTXF alone) was given 50 mg/kg of PTXF every 12 h and saline every 6 h. The fourth group (controls) received an equal volume of saline every 6 h. All animals were kept in the above protocol for 4 d, receiving a total of 16 treatments.
Methods
6 h after the last injection on day 5, the mice were inspected and their appearance and activity level were graded and scored on the following morbidity scale: 1, normal; 2, decreased activity; 3, ruffled fur, moved only with prompting; 4, moribund; 5, died.
Mice were then anesthetized with 50 mg/kg of pentobarbital, and blood was obtained for a complete blood count, serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase, and determination of serum TNF level quantitated by an ELISA kit (Genzyme Corp., Cambridge, MA).
Samples ofthe lung, liver, jejunum, heart, pancreas, kidney, spleen, and thymus were excised. These samples were then fixed in 10% phosphate-buffered formaldehyde, dehydrated in graded alcohols and embedded in paraffin. At least eight sections of each organ from each animal were stained with hematoxylin and eosin. The identity of the tissue was coded, and the slides were randomly graded for lymphocytic infiltration. The remaining heart, liver, and splenic tissue, as well as a 3-cm section ofjejunum, one lung, and one kidney were then removed, weighed, and immediately frozen. They were next lyophilized at -50°C for 24 h and weighed to determine the wet/dry weight ratio as a measurement of organ edema.
The second series of experiments evaluated the effects of IL-2 and PTXF in tumored female C57BL/6 mice. In these experiments mice were given mild pentobarbital anesthesia (25 mg/kg) by intraperitoneal injection, and 0.2 ml of the tumor cell suspension (-300,000 cells) was injected into their tail veins (6). 4 d after tumor cell injection, all animals were randomly divided into four groups (Table I ). Mice were then treated for 4 d with combinations of either IL-2, PTXF, or saline, according to the dose and schedule outlined previously for the nontumored groups. 28 d after tumor cell injection, the mice were graded and scored on the morbidity scale and killed. Thoracotomy was performed after pentobarbital overdose (100 mg/kg) and the lungs were injected with a solution comprising 15% India Ink and 1% ammonia via a small cannula placed in the trachea. The tumors were then "bleached" for 24 h in Fekete's solution containing 100 ml of 70% alcohol, 10 ml of formaldehyde, and 5 ml ofglacial acetic acid (6 (Table I) . There was no difference in the histological findings of nontumored mice treated with either PTXF alone or the saline control. However, significant histological differences existed between the controls and animals treated with IL-2 alone (Table II). Nontumored mice that were treated with IL-2 alone had a marked degree of lymphocytic infiltration of the vascular walls and perivascular spaces of venules, capillaries, and small arterioles in the lung, liver, pancreas, and small bowel mesentery (Table II) . Pulmonary alveolar septa were markedly thickened and alveoli frequently contained erythrocytes, macrophages, and abundant lymphocytes. There was a marked lymphocytic infiltration ofhepatic portal triads and central venular areas and occasional areas of hepatic necrosis. The heart was normal except for a few lymphoid cells in the epicardium.
Significantly less lymphocytic infiltration was seen in the lung, liver, pancreas, and small bowel mesentery in the IL-2 and PTXF group as compared to mice treated with IL-2 alone. However, the group receiving both IL-2 and PTXF did have more lymphocytes present than controls. In contrast to the IL-2-induced lymphocytic infiltration observed in most organs, there was significant depletion ofthymic lymphocytes in mice treated with either IL-2 alone or with a combination of IL-2 and PTXF (Table II) . There was no significant difference in multiple organ edema (wet/dry weight ratios) in mice treated with either saline or PTXF (Table II) , except for the spleen where significantly less edema was observed in mice treated with PTXF. Mice treated with IL-2 alone had increased edema in the lung, liver, jejunum, and spleen. The addition of PTXF prevented IL-2-induced edema in these organs.
IL-2 significantly increased the circulating serum level of TNF (Table II) . The combination of PTXF and IL-2 significantly suppressed IL-2-induced increases in circulating TNF. PTXF also increased the number of circulating white blood cells and lymphocytes as compared to controls (Table II) , presumably because of the inhibition of leukocyte margination and adhesion. IL-2 caused leukopenia, lymphopenia, and thrombocytopenia 4 d after therapy. The addition of PTXF to IL-2 therapy resulted in a lymphophilia as compared to controls. The IL-2-induced leukopenia and thrombocytopenia were also blocked by PTXF. IL-2 induced hepatic dysfunction manifested by increased serum transaminase levels, and PTXF inhibited the IL-2-induced hepatic dysfunction but had no effect on liver function by itself. Tail vein injections ofa tumor cell suspension ofMCA-105 fibrosarcoma cells resulted in a large number of pulmonary metastases both in the control group and the group treated with PTXF alone. The number of metastases and the index of tumor surface area were significantly reduced by IL-2 treatment (Table III) . The addition ofPTXF to IL-2 therapy did not alter the antitumor efficacy of IL-2 (Table III and Fig. 1 ).
Discussion
In these studies, PTXF did not alter the antitumor efficacy of IL-2 but it did inhibit many of the indices of IL-2 toxicity. PTXF suppressed IL-2-induced elevation of circulating TNF, it decreased IL-2-induced lymphocytic infiltration, and it decreased IL-2-induced multiple organ edema. It also inhibited IL-2-induced increases in circulating liver enzymes and it decreased IL-2-induced morbidity and mortality. These toxic effects ofIL-2 are consistent with previous reports (2) and are the current primary limitation to the clinical application ofIL-2 as an effective antineoplastic agent. Several studies have evaluated the mechanism of the vascular leak syndrome and identified potential inhibitors (2) , but, to date, no clinically approved drugs have been identified that reduce toxicity and at the same time preserve antitumor efficacy. Our study identifies PTXF as an agent with the potential for extending the therapeutic efficacy of IL-2.
In vivo evidence shows that IL-2 induces the production of other cytokines that are potentially important in mediating IL-2 toxicities. IL-2 induces macrophage TNF gene expression in vivo (4, 1 1), and elevated circulating levels of TNF have been detected in patients treated with IL-2 (5, 12). Mier et al. (5) have also demonstrated that patients treated with IL-2 have increased circulating levels of TNF temporally consistent with the onset of fever and other toxic manifestations of IL-2.
The current study also demonstrated elevated plasma levels of TNF after IL-2 therapy (Table II) . IL-2 has no direct effect on endothelial permeability (13) , but TNF induces acute pulmonary vascular endothelial injury and increases vascular permeability (14, 15) . Skin biopsies of patients treated with IL-2 demonstrate the expression of endothelial leukocyte adhesion molecules (16) . It is TNF, and not IL-2, that induces the ex- Several recent reports have documented the PTXF-mediated suppression of TNF production (7, 8) , but, to the best of our knowledge, the current report is the first to correlate the PTXF attenuation of IL-2-induced toxicity with the synchronous PTXF suppression of circulating plasma levels of TNF. Most importantly, despite the PTXF inhibition of IL-2 toxicity, IL-2 antitumor efficacy was still present with PTXF treatment (Table III) (20) . These findings strongly suggest that the mechanism of the vascular leak syndrome involves LAK cells.
Our study extends the findings of these previous reports in showing that mice treated with IL-2 alone had changes in lymphocyte distribution (Table II) that correlated with the development of toxicity (Tables I and II) . IL-2 therapy resulted in the depletion of thymic lymphocytes, the development of peripheral lymphopenia, and the formation of lymphoid infiltrates in the lung, liver, small bowel mesentery, and pancreas.
PTXF remarkably altered the distribution of IL-2-activated lymphocytes but did not interfere with the IL-2-induced mobilization of lymphocytes, in that mice treated with IL-2 alone and those treated with IL-2 and PTXF both had similar degrees of thymic depletion (Table II) . Mice treated with a combination of IL-2 and PTXF had much larger numbers of circulating lymphocytes in peripheral blood than mice treated with IL-2 alone, but they had a marked decrease in the number of lymphocytes infiltrating into the parenchyma of various organs (Table I) . We believe that the current report is also the first observation of the PTXF suppression of IL-2-induced lymphocyte trafficking from the intravascular space to the parenchyma of various organs. The resultant reduction in lymphocytic infiltration in various organs may be another mechanism in the PTXF prevention ofmultiple organ edema, dysfunction, and associated morbidity and mortality of IL-2 therapy.
Despite this PTXF-mediated redistribution of lymphocytes, IL-2 still maintained its antitumor efficacy ( Fig. 1 and Table III 
